Most LAM cases are sporadic and somatic inactivation of TSC2 in an unknown cell type(s) is expected to be the central genetic alteration necessary for disease development (Carsillo et al, 2000). The gene discussed is TSC2; the disease is lymphangioleiomyomatosis.